zotatifin + trastuzumab

**zotatifin + trastuzumab** is an experimental combination therapy under clinical investigation for advanced solid tumors, particularly **HER2-positive breast cancer**. Zotatifin (eFT226) is a selective inhibitor of eukaryotic initiation factor 4A (eIF4A), a key RNA helicase involved in the initiation of protein translation; by inhibiting eIF4A, zotatifin suppresses the production of oncogenic proteins and can synergize with other therapies to block cancer growth[4][5][7]. Trastuzumab is a well-established humanized monoclonal antibody that targets the HER2/ERBB2 receptor, blocking downstream signaling and inducing antibody-dependent cellular cytotoxicity. The rationale for the combination comes from preclinical and early clinical evidence suggesting enhanced activity when zotatifin, which broadly suppresses cancer-driving protein synthesis (including resistance pathways), is paired with trastuzumab's targeted HER2 blockade. Phase 2a and earlier studies are evaluating this combination, alone or with additional agents, in HER2-positive advanced breast cancer and other solid tumors[7][5].